Co-amlessa pills 4mg/10mg/1.25mg №10×3

Co-Amlessa Tablets: Effective Blood Pressure Control with a Triple Action Formula

Co-Amlessa tablets offer a unique and powerful combination of three active ingredients to effectively manage high blood pressure:

• Perindopril: An ACE inhibitor that blocks the production of a substance that narrows blood vessels.
• Indapamide: A diuretic that helps the body eliminate excess fluid and salt, reducing blood pressure.
• Amlodipine: A calcium channel blocker that relaxes blood vessels, allowing for easier blood flow.

This triple action formula works synergistically to provide comprehensive blood pressure control.

Co-Amlessa is available in the following dosages:

• 4 mg/10 mg/1.25 mg: White or almost white, oval, biconvex tablets with a score on one side.
• 8 mg/10 mg/2.5 mg: White or almost white, round, biconvex tablets with a score on one side.

Who can benefit from Co-Amlessa?

Co-Amlessa is prescribed for individuals whose high blood pressure is effectively managed with a fixed combination of perindopril, indapamide, and amlodipine at the same dosages.

Important safety information:

Contraindications:

• Severe renal insufficiency (creatinine clearance < 30 ml/min)
• Moderate renal impairment (creatinine clearance 30-60 ml/min) for dosages of 8 mg/5 mg/2.5 mg and 8 mg/10 mg/2.5 mg
• Severe liver dysfunction
• Pregnancy and lactation

Precautions:

• Hypovolemia: Risk of hypotension, especially in patients with low blood pressure, renal artery stenosis, congestive heart failure, or cirrhosis.
• Electrolyte disturbances: Risk of hypokalemia and hyperkalemia, particularly in patients with diabetes mellitus or renal insufficiency.
• Renal function: Monitoring of potassium and creatinine levels is essential, especially in patients with renal impairment.
• Atherosclerosis: Risk of hypotension, especially in patients with ischemic heart disease or cerebrovascular insufficiency.
• Heart failure: Requires careful monitoring and lower starting doses.
• Hypertension crisis: Safety and efficacy not established.
• Surgery/Anesthesia: ACE inhibitors may cause hypotension during anesthesia.
• Liver failure: Risk of cholestatic jaundice and fulminant hepatic necrosis.
• Elderly patients: Dosage adjustments and close monitoring are crucial.
• Ethnic characteristics: Perindopril may be less effective in black patients.
• Diabetes mellitus: Regular monitoring of blood glucose is required.

Interactions with other drugs:

• Lithium: May increase lithium levels and risk of toxicity.
• Aliskiren: Increased risk of hyperkalemia, impaired renal function, cardiovascular morbidity and mortality.
• Potassium-sparing diuretics: Increased risk of hyperkalemia.
• ACE inhibitors: Risk of hypotension, hyperkalemia, and impaired renal function.
• Angiotensin II receptor blockers: Not recommended for simultaneous use.
• Non-steroidal anti-inflammatory drugs (NSAIDs): May decrease the hypotensive effect and increase risk of renal impairment.
• Antidiabetic drugs (insulin, oral hypoglycemic agents): May increase hypoglycemic effect.
• Dantrolene: Risk of cardiovascular failure and ventricular fibrillation.
• Grapefruit juice: May enhance the blood pressure-lowering effect.

Note: This information is not a substitute for professional medical advice. Always consult with your healthcare provider before starting any new medication.